Incyte Corp
Q1 2026 Earnings
Market Reaction
S&P 500 over the same 30 days: +6.29%.
Did INCY Beat Earnings? Q1 2026 Results
Incyte Corporation posted a blowout first quarter for 2026, with earnings per share of $1.81 beating the $1.34 consensus estimate by 35.13% and revenue of $1.27 billion topping expectations by 4.65% while climbing 20.9% year over year. The standout driver was broad-based commercial momentum across the portfolio, headlined by Jakafi's 7% growth to $757.75 million and a surging hematology and oncology segment that rose 116% to $204 million, fueled by rapid uptake of newer launches including Zynyz and Niktimvo. Operating leverage was on full display as well, with GAAP operating income rising 47% to $301.12 million even as R&D investment climbed 18% to $515.90 million to support 10 active Phase 3 programs. With institutional ownership approaching 97%, investor confidence in the pipeline appears well-anchored. Incyte reaffirmed its full-year 2026 guidance for total net sales of $4.77 to $4.94 billion and is positioning for four product approvals and launches stretching from mid-2026 into early 2027, including povorcitinib in hidradenitis suppurativa and the anticipated Jakafi XR rollout.
- Jakafi net sales grew 7% driven by 6% increase in paid demand across all indications
- Opzelura net sales grew 20% driven by increased patient demand in atopic dermatitis and vitiligo
- Hematology and Oncology portfolio net sales grew 116% driven by Niktimvo, Monjuvi/Minjuvi, and Zynyz in SCAC
- Niktimvo net sales grew 305% year-over-year
- Zynyz net sales grew 1,276% year-over-year following first-line SCAC launch
- Product royalty revenues grew 16% to $151 million
- $17 million in milestone and contract revenues earned in Q1 2026
- SG&A expenses grew only 1% year-over-year, demonstrating operating leverage
“Our first quarter represented a strong start to 2026, driven by 20% year-over-year net sales growth and strong commercial execution. At the same time, we are making significant progress toward building a more durable, growth oriented portfolio with four anticipated product approvals and launches over the next 12 months, positive registrational data for povorcitinib in vitiligo and a late stage pipeline that now includes 10 Phase 3 studies underway, including the initiation of a pivotal trial of our G12D inhibitor in first line pancreatic ductal adenocarcinoma.”
Incyte CEO, on the earnings call
Forward Guidance & Outlook
Incyte reaffirmed its full-year 2026 financial guidance across all categories: total net sales of $4,770–$4,940 million, Jakafi net sales of $3,220–$3,270 million (including initial Jakafi XR launch), Opzelura net sales of $750–$790 million (including anticipated EU approval for moderate atopic dermatitis in H2 2026), and Hematology and Oncology net sales of $800–$880 million. Total GAAP R&D and SG&A operating expenses are expected to be $3,495–$3,675 million, and Non-GAAP R&D and SG&A of $3,205–$3,375 million. The company anticipates four product approvals and launches from mid-2026 into early 2027, including Jakafi XR (U.S. mid-2026), Opzelura in moderate AD (EU H2 2026), and povorcitinib in HS (EU late 2026, U.S. Q1 2027).
INCY YoY Financials
INCY Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.